# Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency

> **NCT02191254** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 245 (actual)

## Conditions studied

- Venous Insufficiency

## Interventions

- **DRUG:** Antistax®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02191254
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2004-10
- **Final completion:** —
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191254, "Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02191254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*